FDA approved Dupixent, developed by Regeneron Pharmaceuticals and Sanofi, at a dosage of 300 mg weekly for the treatment of patients with eosinophilic esophagitis aged 12 years and older, weighing at least 40 kg. Dupixent was the first and only drug in the U.S. specifically designed to treat eosinophilic esophagitis.